Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. (ZTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. trades at $19.97 (market cap $15.32B). The key difference: ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. is far larger — about 2.1× Spyre Therapeutics Inc. Common Stock's market cap, and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. pays a 3.39% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| SYRE | ZTO | |
|---|---|---|
Market Cap | $7.35B | $15.32B |
Volume | 1,624,631 | 2,342,996 |
Sector | Health | Industrials |
52-Week High | $108.92 | $25.88 |
52-Week Low | $22.18 | $18.59 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $6.35B | $13.94B |
Dividend Yield | — | 3.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
ZTO Express trades at $20.67, up 1.08% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with $49.1B revenue, 19.03% net margin, and attractive valuation at P/E of 10.79. Recent Q2 2026 earnings beat expectations with 11% EPS growth, while analyst consensus remains strongly positive with 70% buy ratings.
ZTO presents compelling value with 50% upside to consensus target of $30.85, supported by pricing power and cost efficiencies. Risks include competitive pressures in China's delivery market and negative cash flow trends. The stock offers growth potential through market share gains and improved pricing environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.
ZTO Express provides domestic and international express delivery services in China. Its network-partner model combines ZTO's sorting and trunk transportation with partners' pickup and last-mile delivery.
Read more on ZTO →
